When do the PERIDEX patents expire, and when will generic PERIDEX be available?

Sponsor	Phase
Stony Brook University	PHASE4
Ohio State University	Phase 4
Montefiore Medical Center	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solventum	PERIDEX	chlorhexidine gluconate	SOLUTION;DENTAL	019028-001	Aug 13, 1986	AT	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 6, 2026

Peridex is a mature prescription oral rinse containing chlorhexidine gluconate 0.12%. Its commercial value comes from brand recognition, dental-channel prescribing, manufacturing scale, and institutional purchasing rather than regulatory exclusivity. U.S. patent protection and FDA marketing exclusivity expired decades ago. Generic chlorhexidine gluconate oral rinses materially limit pricing power, while Peridex retains demand in periodontal care, post-procedure treatment, and dental practices.

Standalone Peridex revenue is not publicly reported. The product is part of a broader oral-health and prescription-product portfolio, and public filings do not identify Peridex sales, gross margin, or unit volume separately. The financial trajectory is therefore best assessed through market maturity, generic competition, dental utilization, pricing, and portfolio ownership.

What is Peridex and how is it used?

Peridex is a prescription oral rinse containing chlorhexidine gluconate 0.12%. The FDA-approved indication is the reduction of gingival inflammation and gingival bleeding associated with gingivitis when used between dental visits as part of a professional oral-health program.[1]

Peridex is generally prescribed as a 15-mL rinse used twice daily for 30 seconds after toothbrushing. Patients are instructed not to swallow the product and not to rinse with water or eat immediately after use. Common adverse effects include tooth staining, increased calculus formation, taste alteration, and oral irritation.[1]

Peridex product profile

Attribute	Peridex
Active ingredient	Chlorhexidine gluconate
Concentration	0.12%
Dosage form	Oral rinse
U.S. status	Prescription drug
Primary indication	Gingivitis
Product category	Antiseptic oral rinse
FDA application	NDA 019962
Primary users	Dentists, periodontists, oral surgeons, dental patients
Main substitutes	Generic chlorhexidine rinses, professional oral-care products, nonprescription antiseptic rinses
Commercial maturity	Mature product with generic competition

Peridex is distinct from over-the-counter consumer rinses such as Listerine and Crest. Those products compete for oral-rinse use but generally do not replicate the prescription chlorhexidine treatment pathway.

What is the FDA regulatory status of Peridex?

Peridex is an FDA-approved prescription drug. Its regulatory position is mature, with no meaningful period of remaining new-drug exclusivity. The product is listed in FDA drug databases under chlorhexidine gluconate oral rinse and is associated with NDA 019962.[1,2]

The product’s regulatory value is based on an established approval, known formulation, recognized clinical use, and continued dentist prescribing. It does not depend on a recent clinical innovation or a new indication.

FDA status and regulatory implications

Regulatory issue	Peridex position
NDA approval	Established FDA approval
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current commercial significance
Prescription status	Yes
ANDA competition	Established
OTC switch	No broad switch has occurred
Regulatory barrier to entry	Low to moderate for a conventional equivalent

A generic sponsor can generally seek approval through an abbreviated new drug application if it demonstrates pharmaceutical equivalence, bioequivalence where applicable, and compliance with manufacturing requirements. The formulation is comparatively straightforward relative to complex injectables, biologics, or modified-release products.

When did Peridex lose patent and market exclusivity?

Peridex’s core patent and FDA exclusivity protections expired long before the current commercial period. The product has been marketed for decades, and generic chlorhexidine gluconate oral rinses are available in the United States.

The practical result is that Peridex has no modern exclusivity wall comparable to a recently approved branded drug. Any remaining intellectual-property protection would be expected to relate to narrow formulation, packaging, manufacturing, or presentation claims rather than the basic chlorhexidine gluconate 0.12% product.

Exclusivity timeline

Period	Commercial position
Initial launch period	Protected prescription product with limited direct generic competition
Patent and NDA exclusivity period	Expired
Generic entry period	Multiple generic chlorhexidine oral-rinse products entered
Current period	Mature branded product competing on prescribing familiarity, supply, and channel access

A definitive current patent-expiration date for a Peridex-specific patent cannot be used as the principal valuation metric because the core product is already exposed to generic competition. The relevant commercial question is whether any active patent claims materially restrict equivalent products. Publicly available product information does not indicate a commercially significant active patent blocking standard generic chlorhexidine oral rinse.

What patents protect Peridex?

The core active ingredient, chlorhexidine gluconate, is long established and cannot support meaningful new chemical entity protection for Peridex. The commercial formulation is also mature.

Potential intellectual-property categories include:

formulation composition;
excipient ratios;
flavoring and dye systems;
container and closure systems;
manufacturing controls;
labeling and method-of-use claims;
packaging configurations.

These categories generally have less blocking power than a composition-of-matter patent. Generic competitors can often design around narrow claims by changing inactive ingredients, packaging, or manufacturing parameters while maintaining the same active ingredient and concentration.

How strong is the Peridex patent estate?

The Peridex patent estate is commercially weak as a barrier to generic entry. Its strength is better characterized as low for core product protection and potentially moderate for narrow manufacturing or presentation claims.

Patent factor	Assessment
Core molecule protection	Expired or unavailable
Core concentration protection	Weak
Formulation differentiation	Limited
Method-of-use protection	Limited for established gingivitis use
Manufacturing protection	Potentially narrow
Packaging protection	Potentially narrow
Generic design-around risk	High
Litigation leverage	Low

The absence of a strong active patent position does not eliminate brand value. Dentists may continue to prescribe Peridex because of familiarity, historical use, perceived consistency, and ordering convenience. Those factors support retention but do not create legal exclusivity.

What formulation patents protect chlorhexidine oral rinses?

Chlorhexidine oral rinses can differ in alcohol content, flavoring, coloring, preservatives, sweeteners, surfactants, and container systems. Formulation differences may affect taste, staining, precipitation, stability, and patient adherence.

Peridex’s commercial formulation has historically been associated with patient complaints involving staining and taste alteration. A competitor offering a more acceptable taste profile or lower perceived staining may gain share, but the clinical and regulatory value of such differentiation depends on whether dentists regard the product as therapeutically interchangeable.

Formulation patents would be most valuable if they provided one of the following:

materially improved stability;
lower staining or calculus formation;
improved taste and adherence;
reduced alcohol exposure;
a clinically meaningful delivery advantage.

A standard chlorhexidine oral rinse does not present the technical complexity of a biologic formulation or a long-acting drug-delivery system. Formulation patents are therefore more likely to support product differentiation than to prevent broad generic substitution.

Are there Paragraph IV challenges to Peridex?

Paragraph IV litigation is not a central current risk factor for Peridex. Paragraph IV certifications are most commercially important when a generic applicant challenges an unexpired Orange Book-listed patent. Peridex’s core market has already experienced generic entry, and the product does not have a recognized active patent barrier comparable to a recently launched branded medicine.

The relevant competitive mechanism is ordinary generic substitution and formulary purchasing rather than a pending patent challenge. Publicly available FDA and court information does not establish a current, material Paragraph IV campaign directed at the core Peridex product.[2,3]

What patent litigation affects Peridex?

Peridex does not appear to have a current litigation profile that materially threatens the U.S. market. Any dispute involving a narrow formulation, trademark, packaging feature, or manufacturing process would be less consequential than a challenge to a blocking composition patent.

The principal legal risks are commercial rather than patent-driven:

trademark enforcement against confusingly similar products;
product-liability claims;
manufacturing and quality actions;
labeling disputes;
supply or distribution agreements;
state substitution and reimbursement disputes.

Who competes with Peridex?

Peridex competes across three commercial groups.

Generic chlorhexidine products

Generic chlorhexidine gluconate 0.12% rinses are the closest substitutes. They compete primarily through lower acquisition cost, wholesaler availability, dental-office purchasing, and pharmacy substitution.

Professional oral-care products

Dental practices may use or recommend products from manufacturers such as Colgate-Palmolive, Procter & Gamble, Sunstar, and other professional oral-care suppliers. These products may include fluoride rinses, antimicrobial rinses, desensitizing products, and post-procedure care products.

Consumer antiseptic rinses

Listerine and other nonprescription rinses compete for general oral-rinse use, but they do not directly replace prescription chlorhexidine in every periodontal or post-surgical setting.

Competitive factor	Peridex	Generic chlorhexidine	OTC oral rinses
FDA prescription indication	Yes	Generally equivalent indication	Usually no
Price	Higher than generics	Lower	Broad range
Dentist familiarity	High	Increasing	High consumer awareness
Generic substitution	Exposed	N/A	N/A
Clinical differentiation	Limited	Limited	Variable
Primary purchasing channel	Dental and pharmacy	Dental, pharmacy, institutional	Retail

What is the commercial market size for chlorhexidine oral rinse?

Public companies do not generally disclose Peridex-specific sales. Market-research estimates for the global oral-rinse market often combine prescription and consumer products, making them unsuitable for valuing Peridex without product-level segmentation.

Peridex’s addressable market is narrower than the total mouthwash market. Demand is concentrated in:

periodontal treatment;
dental surgery and extraction aftercare;
implant and oral-surgery practices;
hospital dental services;
patients with short-term gingival inflammation;
dental practices that dispense or recommend prescription rinses.

The product is unlikely to have the volume characteristics of a mass-market consumer brand. Its economic profile is closer to a mature specialty prescription product with recurring but limited treatment duration.

What is Peridex’s financial trajectory?

Peridex’s financial trajectory is likely characterized by stable-to-declining branded sales, continuing generic price pressure, and relatively resilient gross margins where brand prescriptions remain insulated from full generic substitution.

No public filing identifies Peridex revenue separately. 3M historically reported products within broad business segments rather than disclosing Peridex sales. Following the 2024 separation of 3M’s health-care business into Solventum, public reporting continues to provide portfolio-level information rather than a standalone Peridex income statement.[4,5]

Financial drivers

Driver	Effect on Peridex
Generic competition	Reduces price and unit share
Dentist prescribing	Supports brand retention
Product familiarity	Protects against rapid abandonment
Dental procedure volume	Drives episodic demand
Insurance coverage	Affects patient access
Institutional contracts	Can increase volume but reduce price
Manufacturing scale	Supports margin preservation
Supply reliability	Can shift share rapidly
Taste and staining complaints	Limit long-term adherence
OTC substitution	Caps broader expansion

A reasonable commercial scenario is:

branded volume remains stable or declines gradually;
net price is pressured by generic substitution and payer controls;
generic volume expands in price-sensitive channels;
Peridex maintains a premium in dentist-directed and institutional settings;
total category demand tracks dental visits, periodontal treatment, oral surgery, and procedural care.

The most material downside would come from a supply disruption, a low-cost generic gaining preferred status, or a competing professional product reducing dentist preference. The most plausible upside would come from improved formulation, better tolerability, stronger dental-distribution execution, or an indication expansion, although no such expansion should be assumed without a new FDA action.

Who owns Peridex and what licensing deals matter?

Peridex has historically been associated with 3M’s health-care business. 3M separated its health-care operations into Solventum in April 2024.[5] Public corporate disclosures do not establish a major Peridex-specific licensing transaction that materially changes the product’s economics.

The commercial importance of ownership is operational rather than patent-based. A portfolio owner can use:

dental sales representatives;
professional education;
distribution contracts;
formulary relationships;
manufacturing and packaging scale;
cross-selling with other dental products.

Because Peridex is mature and genericized, a licensing transaction would likely be valued on cash flow, distribution reach, manufacturing cost, and brand retention rather than remaining patent life.

What generic launch scenarios exist for Peridex?

Base case: continued generic substitution

Generic chlorhexidine products maintain or increase share. Peridex remains available as a branded option, with demand concentrated among dentists and institutions that value established supply and product recognition.

Downside case: accelerated brand erosion

A generic receives preferred formulary placement, offers reliable supply, and gains dental-distributor visibility. Peridex loses prescription volume and faces greater price concessions.

Upside case: brand retention through professional channels

Peridex preserves share through dentist familiarity, direct professional distribution, and dependable availability. Revenue remains flat or declines slowly despite generic competition.

Disruption case: manufacturing or regulatory event

A recall, shortage, quality issue, or labeling action could temporarily shift demand between Peridex and generic suppliers. In a mature category, supply reliability can matter more than patent status.

What is the geographic coverage of Peridex?

Peridex’s strongest commercial relevance is in the United States, where the product has an established FDA prescription identity and dental-market recognition. International chlorhexidine oral-rinse markets are fragmented by brand, registration, formulation, prescription status, and local dental practice.

Geographic expansion is constrained by:

country-specific regulatory approvals;
local product registrations;
trademark ownership;
local generic suppliers;
reimbursement rules;
dental-distribution networks;
country-specific formulation requirements.

The United States remains the most relevant market for assessing Peridex’s branded economics and generic exposure.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate but manageable. The product requires pharmaceutical-grade active ingredient, validated mixing and filling processes, microbial controls, packaging compatibility, stability testing, and compliant labeling. These requirements can exclude small or poorly capitalized suppliers, but they do not create a high barrier comparable to sterile injectables or biologic manufacturing.

The principal operational risks are:

chlorhexidine raw-material supply;
preservative and excipient consistency;
microbial contamination control;
stability and precipitation;
bottle and closure compatibility;
taste and color consistency;
contract-manufacturing capacity.

Manufacturing competence can protect short-term share during shortages, but it is unlikely to sustain a long-term premium without brand or clinical differentiation.

Key Takeaways

Peridex is a mature prescription chlorhexidine gluconate 0.12% oral rinse.
Core patent and FDA exclusivity protections have expired.
Generic chlorhexidine products are the principal competitive threat.
Current Paragraph IV litigation is not a material driver of the product’s outlook.
Formulation and manufacturing patents may exist in narrow areas but do not appear to block standard generic competition.
Standalone Peridex revenue is not publicly disclosed.
Financial performance is likely stable to declining, with pressure from generic substitution and payer purchasing.
Brand resilience depends on dentist familiarity, distribution, supply reliability, and institutional relationships.
Peridex has limited biosimilar relevance because it is a small-molecule oral rinse, not a biologic.
The product’s remaining value is commercial and operational rather than exclusivity-driven.

FAQs

Is Peridex still under patent protection?

The core Peridex product is not protected by a commercially meaningful active patent barrier. Any surviving claims would likely concern narrow formulation, packaging, or manufacturing features.

Is Peridex interchangeable with generic chlorhexidine gluconate?

Generic products approved as therapeutically equivalent may be substitutable under applicable state and pharmacy rules. Product-level substitution depends on FDA equivalence listings, state law, payer policy, and prescription instructions.

Does Peridex have biosimilar competition?

No. Biosimilar rules apply to biological products. Peridex is a small-molecule chlorhexidine gluconate oral rinse.

Can Peridex be purchased over the counter?

Peridex is marketed as a prescription product in the United States. Nonprescription antiseptic rinses are available, but they are not automatically equivalent substitutes for prescription chlorhexidine.

What would increase Peridex’s value in an acquisition?

The strongest value drivers would be durable dental-channel prescribing, reliable manufacturing, favorable generic substitution economics, institutional contracts, geographic registrations, and evidence that the brand retains a price premium despite generic availability.

References

U.S. Food and Drug Administration. (n.d.). Peridex chlorhexidine gluconate oral rinse prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Peridex, NDA 019962. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
3M Company. (2024). 2023 annual report. 3M.
Solventum Corporation. (2025). Annual report for fiscal year 2024. Solventum.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	11
What excipients (inactive ingredients) are in PERIDEX?	PERIDEX excipients list
DailyMed Link:	PERIDEX at DailyMed

AI Deep Research

Questions you can ask:

Summary for PERIDEX

Recent Clinical Trials for PERIDEX

Pharmacology for PERIDEX